Trial · NCT03943667
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
NCT03943667, Phase 3, Completed, UNICANCER; results first posted 2026-01-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma. Trials, record NCT03943667. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03943667
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
- NCT number
- NCT03943667
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 211 participants, actual
- Lead sponsor
- UNICANCER
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, Paclitaxel
- First posted
- 2019-05-09
- Last updated
- 2026-01-15
- Other registries' IDs
- eudract:2018-002886-21
- Results first posted
- 2026-01-15
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | Until death (life expectancy around 12 months) | Time from the date of randomization to the date of death from any cause |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival | Until death (life expectancy around 12 months) | months | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | GEMPAX | 6.4 | 95% Confidence Interval 5.2 to 7.4 | months | |
| Overall Survival | Control | 5.9 | 95% Confidence Interval 4.6 to 6.9 | months |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | GEMPAX | 140 | |
| Overall Study | STARTED | Control | 71 | |
| Overall Study | COMPLETED | GEMPAX | 140 | |
| Overall Study | COMPLETED | Control | 71 | |
| Overall Study | NOT COMPLETED | GEMPAX | 0 | |
| Overall Study | NOT COMPLETED | Control | 0 |
Source ClinicalTrials.gov
Adverse events224
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | GEMPAX | 21 | 140 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Control | 3 | 71 | |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | GEMPAX | 2 | 140 | |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Control | 0 | 71 | |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | GEMPAX | 2 | 140 | |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Control | 0 | 71 | |
| other | NEUTROPENIA | Blood and lymphatic system disorders | GEMPAX | 22 | 140 | |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Control | 11 | 71 | |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | GEMPAX | 20 | 140 | |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Control | 3 | 71 |
1 to 10 of 224Source ClinicalTrials.gov
See all 224 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | GEMPAX | 131 | 140 |
| Total, all-cause mortality | Control | 68 | 71 |
| Total, other adverse events | GEMPAX | 138 | 140 |
| Total, other adverse events | Control | 22 | 71 |
| Total, serious adverse events | GEMPAX | 71 | 140 |
| Total, serious adverse events | Control | 26 | 71 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| GEMPAX vs Control: deaths from any cause | Trial comparisons |
| GEMPAX vs Control: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03943667
GET https://conductscience.org/api/trials/v1/NCT03943667/events?page=2